The FDA has granted priority review to brensocatib to treat patients with non-cystic fibrosis bronchiectasis, according to a ...

The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for ...

BRIDGEWATER, N.J. - Insmed Incorporated (NASDAQ:INSM), a biopharmaceutical company with a market capitalization of $14.57 ...

Patients with bronchiectasis in China have a high disease burden and a low rate of use of evidence-based treatments.

Stifel analysts maintained their Buy rating on Insmed shares (NASDAQ:INSM) and increased the price target from $88.00 to $97.00. According to InvestingPro data, the stock has delivered an impressive ...

Shares in Insmed have rocketed after the biotech reported positive results in a highly-anticipated clinical trial of brensocatib in the respiratory disorder bronchiectasis. The phase 3 trial ...

Insmed's promising drug pipeline includes Brensocatib and Arikayce. See why INSM stock is a strong pick with multi-billion ...

The Bridgewater, N.J., biopharmaceutical company said brensocatib has the potential to become the first and only approved treatment for non-cystic fibrosis bronchiectasis, which causes the lungs' ...

The US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for brensocatib for patients with ...

Find effective medications for 'Bronchiectasis treatment right here!' This page is a trusted source for both professionals and patients, detailing brand-name and generic options designed to manage ...

Insmed (INSM) announced that the U.S. FDA has accepted the company’s New Drug Application for brensocatib for patients with non-cystic fibrosis ...

Seven-year-old Harmony from Sheffield is supporting The Children’s Hospital Charity by taking part in Theo’s Pyjama Day in ...